LPD lipase Inhibitors
LPD lipase inhibitors are a class of chemical compounds that specifically target lipase enzymes responsible for the breakdown of lipids. Lipases, particularly those involved in lipid hydrolysis, play a critical role in catalyzing the cleavage of ester bonds in triglycerides, which are then converted into fatty acids and glycerol. Lipase enzymes are found in various tissues, such as the pancreas, liver, and adipose tissue, and their activity is essential for the digestion, absorption, and metabolism of dietary fats. By inhibiting the activity of these enzymes, LPD lipase inhibitors modulate lipid processing, altering the normal metabolic pathways associated with lipid degradation. This inhibition impacts the biochemical processes governing lipid homeostasis and can influence cellular energy balance and the distribution of lipid stores within biological systems.
On the molecular level, LPD lipase inhibitors function through various mechanisms, including competitive inhibition, where they directly bind to the active site of lipase enzymes, blocking their interaction with substrate molecules. Other inhibitors may act through allosteric modulation, altering the enzyme's conformation and reducing its catalytic efficiency. Structural studies of lipase-inhibitor interactions reveal the importance of hydrophobic and electrostatic interactions in stabilizing the inhibitor within the enzyme's active site. Additionally, the specificity of these inhibitors can vary based on their chemical structure, allowing them to target different classes of lipases, such as triacylglycerol lipases or phospholipases, depending on the inhibitor's design. The fine-tuning of these molecular interactions enables researchers to study the functional role of lipases in lipid metabolism, contributing to a deeper understanding of lipid regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
Lipase Inhibitor, THL may directly inhibit gastrointestinal lipases, which could lead to a feedback downregulation of LPD lipase expression by increasing intracellular lipid levels. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $187.00 $843.00 | 14 | |
This compound could reduce LPD lipase expression by decreasing triglyceride biosynthesis, as it inhibits long-chain acyl-CoA synthetase, thus reducing the pools of acyl-CoA required for triglyceride assembly and potentially altering lipid signaling. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By incorporating into DNA and RNA, 5-Azacytidine could disrupt the methylation pattern on the LPD lipase gene promoter, potentially leading to decreased transcription and subsequent downregulation of LPD lipase expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A may repress LPD lipase expression by inhibiting histone deacetylase activity, leading to hyperacetylation of histones and a closed chromatin conformation that is less conducive to gene transcription. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
As a PPARγ agonist, Rosiglitazone could decrease LPD lipase expression by altering the transcriptional activity of genes involved in lipid uptake and storage, potentially leading to a reduced need for LPD lipase activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin could inhibit the synthesis of mevalonate, a precursor in the cholesterol biosynthesis pathway, potentially leading to a homeostatic decrease in LPD lipase expression as part of a broader reduction in lipid biosynthetic activity. | ||||||
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $200.00 $680.00 | 18 | |
By inhibiting ceramide synthase, Fumonisin B1 could disrupt sphingolipid metabolism, which may lead to a decrease in LPD lipase expression due to altered lipid signaling cascades that control lipid metabolism genes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This MAPK pathway inhibitor could decrease LPD lipase expression by preventing the activation of transcription factors that are necessary for the upregulation of the LPD lipase gene. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR signaling, which is crucial for protein synthesis and cell growth, potentially leading to a targeted decrease in LPD lipase expression as the cell downregulates metabolic processes. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate, through PPARα activation, could lead to a decrease in LPD lipase expression as part of a broader shift in gene expression profiles that favor increased lipid oxidation over lipid storage. | ||||||